NTT
29.1.2020 08:34:10 CET | Business Wire | Press release
NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/
1. Background
In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the workload of teachers is increasing, and there is a growing need for efficient and effective safety measures according to those in the field of school education. In order to respond to such needs, NTT Group aims to develop smart campus solutions that contribute to the strengthening of school safety with Denenchofufutaba Gakuen. This will leverage ICT solutions based on the system integration and application development capabilities of the public safety experience gained by providing smart city solutions*1 to the City of Las Vegas, in the United States.
2. Outline of the Joint Study
This joint study aims to build a data aggregation infrastructure that enables situational awareness of danger in the school by using high-resolution video cameras, audio sensors and IoT devices, analyze and predict dangerous events for students, and verify the solutions that contribute to strengthening school safety measures.
(1) Solution Features
The first step starts with the implementation of a system to monitor and report the traffic of vehicles and establish a system to ensure the safety of students when they move between school buildings. Through the operation of this system, the future needs of safety measures and solutions are studied to create new solutions that enables situation analysis uses AI, machine learning technology and 5G related technology.
The data aggregation infrastructure is built on the architecture of NTT's innovative Cognitive Foundation ®*2 , which enables the remote creation, management, and operation of ICT resources, from devices and networks to the cloud.
(2) Points to be verified through Joint Study
Based on the operation of the above solution, the following will be developed with Denenchofufutaba Gakuen.
1) Identification of safety measures in school facilities
2) Identification of technical issues in system integration and operations
3) Creation of solutions using ICT technology
4) Feasibility study as a repeatable campus solution
(3) Period and location of implementation
- Period: Start from February 2020
- Location: Denenchofufutaba Gakuen Campus
(4) Role of each company
NTT Group |
NTT |
Overall supervision and coordination among group companies |
NTT DATA |
Joint planning, environment set-up and solution implementation
|
|
NTT COMWARE |
Multi-Orchestrator delivery and technical support |
|
NTT Communications |
Provision of cloud environment and technical support, Support for Multi-Orchestrator installation |
|
NTT Ltd |
Support for deployment and technical support of smart city solutions as per the City of Las Vegas implementation |
|
NTT East |
Provision of access network, support for network related technologies |
|
Denenchofu Futaba Gakuen |
Joint study planning support (Providing issues and needs) |
|
3. For the Future
In the future, with the learning from this joint study with Denenchofufutaba Gakuen, NTT Group will contribute to the enhancement of school safety by creating new smart campus solutions in the second quarter of 2020.
*1 (press release) About the smart city solutions available in Las Vegas, USA
https://www.ntt.co.jp/news2018/1812/181208a.html
*2 "Cognitive Foundation" is a registered trademark of Nippon Telegraph and Telephone Corporation in Japan.
About NTT
NTT is a Global Technology and Business Solutions Provider. We help clients accelerate growth and innovate new digital business models of the future. We provide business consulting and technology services for global networks, cybersecurity, managed IT and applications, workplace, datacenter and cloud services all supported by our deep industry expertise and innovation.
As a top five Global IT Services provider, our globally diverse and inclusive workforce supports clients in 80+ countries and regions. This includes 85% of the Fortune Global 100 companies and thousands of other clients and communities. With a 120-year heritage of service, innovation and social responsibility, we always advocate and act for our clients and a sustainable future. For more information on NTT, visit www.global.ntt/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005916/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom